Skip to main content

A multimarker approach that includes inflammatory markers can aid in risk stratification

Numerous studies have demonstrated the utility of a multimarker approach to stratifying cardiovascular disease.1,2,3 When combined with standard lipid testing, inflammatory marker testing allows for additional risk stratification, and may be considered for patients with4:

  • Low-to-moderate risk, identified as >5% of the estimated CVD risk
  • Established cardiovascular disease
  • Diabetes
  • Hypertension
  • Metabolic syndrome, as defined by having any 3 of 5 conditions: central obesity, elevated triglycerides, low HDL-C, elevated blood pressure, or elevated plasma glucose
  • Dyslipidemia

Go beyond traditional risk factors. Learn more about inflammatory marker testing:

  • Download the Cardio IQ® Advanced Cardiovascular testing brochure
  • Contact us

Uncovering hidden risk: the importance of inflammatory markers

Monitoring a patient’s inflammatory status may help you to uncover hidden risk from early to advanced stages of cardiovascular disease. With deeper insights, you can take further action to help reduce your patients’ cardiovascular risk.

Learn More

    This information is provided for informational purposes only and is not intended as medical advice. A physician’s test selection and interpretation, diagnosis, and patient management decisions should be based on his/her education, clinical expertise, and assessment of the patient.

     

    References

    1. Penn MS, Klemes AB. Multimarker approach for identifying and documenting mitigation of cardiovascular risk. Future Cardiol. 2013;9(4):497-506. doi:10.2217/fca.13.27

    2. Ikonomidis I, Mihalakeas CA, Lekakis J, et al. Multimarker approach in cardiovascular risk prediction. Dis Markers. 2009;26(5-6):273-285. doi:10.3233/DMA-2009-0633

    3. Libby P, Ridker PM, Hansson GK, et al. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54(23):2129-2138. doi:10.1016/j.jacc.2009.09.009

    4. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.

     

     

During the COVID-19 health crisis, fast action and trusted information matter more than ever.

Find out what's happening

Learn More